What is Infervision?
Infervision leverages advanced AI technology to enhance detection and treatment options for patients in the healthcare sector, offering innovative solutions for hospitals and medical organizations. Their product lineup includes advanced imaging systems such as InferRead for various diagnostic applications and InferOperate for surgical planning and reconstruction. Infervision primarily serves radiologists, surgeons, researchers, and healthcare teams, aiming to improve patient outcomes and streamline hospital operations. With a presence in over 25 countries and a strong portfolio of patents and publications, Infervision is committed to integrating seamlessly into existing workflows in the medical field. The company occupies a pivotal position in the health-tech ecosystem, bridging the gap between complex data analytics and clinical decision support.
How much funding has Infervision raised?
Infervision has raised a total of $165M across 3 funding rounds:
Series A
$8M
Series B
$18M
Series D
$139M
Series A (2017): $8M, investors not publicly disclosed
Series B (2017): $18M led by Qiming Venture Partners, Genesis Capital, and Sequoia Capital China
Series D (2021): $139M supported by Z-Park Fund, CCB Trust, and Goldman Sachs
Key Investors in Infervision
Qiming Venture Partners
A prominent venture capital firm focused on early-stage and growth-stage investments in the healthcare and technology sectors.
Genesis Capital
Genesis Capital, LLC is an independent investment and merchant banking firm focused on key growth sectors of the economy, providing tailored solutions for strategic growth initiatives.
Sequoia Capital China
A global investment firm with an unparalleled track record of partnering with entrepreneurs to create market leaders, managing significant capital across venture and growth stages.
What's next for Infervision?
With the infusion of capital from its latest financing round, Infervision is well-positioned to deepen its R&D efforts and expand its footprint in the global medical imaging market. The strategic focus will likely center on enhancing the interoperability of its AI platforms within existing hospital information systems, thereby reducing the friction of clinical adoption. As the company moves beyond its current growth stage, it will prioritize the scaling of its InferRead and InferOperate suites to meet the rising demand for precision medicine. By leveraging its extensive patent portfolio and international presence, Infervision aims to solidify its status as a standard-bearer for AI-driven diagnostic excellence, potentially exploring further integration with surgical robotics and predictive analytics to capture a larger share of the enterprise healthcare market.
See full Infervision company page
